Kute Vivek B, Shah Priyadarshini S, Vanikar Aruna V, Gumber Manoj R, Patel Himanshu V, Engineer Divyesh P, Shah Pankaj R, Modi Pranjal R, Shah Veena R, Rizvi Syed Jamal, Trivedi Hargovind L
Department of Nephrology and Clinical Transplantation, Institute of Kidney Diseases and Research Center, Dr HL Trivedi Institute of Transplantation Sciences [IKDRC-ITS], Ahmedabad, India.
Transpl Int. 2014 Oct;27(10):1015-21. doi: 10.1111/tri.12373. Epub 2014 Aug 22.
Because access to transplantation with HLA-desensitization protocols and ABO incompatible transplantation is very limited due to high costs and increased risk of infections from more intense immunosuppression, kidney paired donation (KPD) promises hope to a growing number of end-stage renal disease (ESRD) patient in India. We present a government and institutional ethical review board approved study of 56 ESRD patients [25 two-way and 2 three-way pairs] who consented to participate in KPD transplantation at our center in 2013, performed to avoid blood group incompatibility (n = 52) or positive cross-match (n = 4). All patients had anatomic, functional, and immunologically comparable donors. The waiting time in KPD was short as compared to deceased donor transplantation. Laparoscopic donor nephrectomy was performed in 54 donors. Donor relationships were spousal (n = 40), parental (n = 13), others (n = 3), with median HLA match of 1. Graft survival was 97.5%. Three patients died with functioning graft. 16% had biopsy-proven acute rejection. Mean serum creatinine was 1.2 mg/dl at 0.73 ± 0.32 months follow-up. KPD is a viable, legal, and rapidly growing modality for facilitating LDRT for patients who are incompatible with their healthy, willing living donor. To our knowledge, this is the largest single-center report from India.
由于采用HLA脱敏方案和ABO血型不相容移植进行移植的机会非常有限,原因是成本高昂以及更强的免疫抑制导致感染风险增加,肾脏配对捐赠(KPD)为印度越来越多的终末期肾病(ESRD)患者带来了希望。我们开展了一项经政府和机构伦理审查委员会批准的研究,研究对象为56例ESRD患者[25对双向配对和2对三向配对],这些患者于2013年同意在我们中心参与KPD移植,进行该移植是为了避免血型不相容(n = 52)或阳性交叉配型(n = 4)。所有患者均有解剖学、功能和免疫学上可比的供体。与尸体供体移植相比,KPD的等待时间较短。54例供体进行了腹腔镜供肾切除术。供体关系为配偶(n = 40)、父母(n = 13)、其他(n = 3),HLA匹配中位数为1。移植肾存活率为97.5%。3例患者移植肾有功能时死亡。16%的患者经活检证实发生急性排斥反应。在0.73±0.32个月的随访时,平均血清肌酐为1.2mg/dl。对于与健康、愿意的活体供体不相容的患者,KPD是一种可行、合法且迅速发展的促进活体亲属肾移植的方式。据我们所知,这是来自印度的最大规模单中心报告。